HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

Benzinga · 3d ago
HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.